15994 Tildrakizumab efficacy for psoriatic arthritis: 24-week analysis of swollen and tender joint counts and pain
Espinoza, Luis R., Ballerini, Rocco, Chou, Richard, Rozzo, Stephen J., Mendelsohn, Alan M.
Published in Journal of the American Academy of Dermatology (01.12.2020)
Published in Journal of the American Academy of Dermatology (01.12.2020)
Get full text
Journal Article
15989 Safety of tildrakizumab in psoriatic arthritis: An interim analysis from a randomized, double-blind, placebo-controlled phase 2b trial
Ritchlin, Christopher T., Strand, Vibeke, Ballerini, Rocco, Chou, Richard, Rozzo, Stephen J., Mendelsohn, Alan M., Kavanaugh, Arthur
Published in Journal of the American Academy of Dermatology (01.12.2020)
Published in Journal of the American Academy of Dermatology (01.12.2020)
Get full text
Journal Article
15964 Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis
Mease, Philip J., Chohan, Saima, García Fructuoso, Ferran J., Gottlieb, Alice B., Chou, Richard, Mendelsohn, Alan M., Ballerini, Rocco, Luggen, Michael
Published in Journal of the American Academy of Dermatology (01.12.2020)
Published in Journal of the American Academy of Dermatology (01.12.2020)
Get full text
Journal Article
Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
Pourcher, Emmanuelle, Fernandez, Hubert H, Stacy, Mark, Mori, Akihisa, Ballerini, Rocco, Chaikin, Philip
Published in Parkinsonism & related disorders (01.02.2012)
Published in Parkinsonism & related disorders (01.02.2012)
Get full text
Journal Article